BioLASCO Taiwan Co., Ltd. (TPEX:6662)
29.35
-0.10 (-0.34%)
Aug 26, 2026, 9:09 AM CST
BioLASCO Taiwan Revenue
BioLASCO Taiwan had revenue of 64.51M TWD in the quarter ending June 30, 2026, a decrease of -8.21%. This brings the company's revenue in the last twelve months to 258.04M, down -8.71% year-over-year. In the year 2025, BioLASCO Taiwan had annual revenue of 262.66M, down -10.20%.
Revenue (ttm)
258.04M
Revenue Growth
-8.71%
P/S Ratio
2.92
Revenue / Employee
2.84M
Employees
91
Market Cap
754.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.66M | -29.83M | -10.20% |
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 238.08M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Vectorite Biomedical | 54.81M |
| Holy Stone Healthcare | 47.51M |